01 1Cipla
01 1TAFAMIDIS
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-13
Pay. Date : 2023-01-25
DMF Number : 37686
Submission : 2022-11-28
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is TAFAMIDIS, with a corresponding US DMF Number 37686.
Remarkably, this DMF maintains an Active status since its submission on November 28, 2022, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 13, 2023, and payment made on January 25, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II
